InsiderTrades

Form 4 for SLS SELLAS Life Sciences Group, Inc.

Accepted 2025-01-14 00:00:00 ET · period of report 2025-01-10 · accession 0001104659-25-003501 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2025-01-14 2025-01-10 SLS Stergiou Angelos M. Pres, CEO, Dir A - Grant $0.00 +500.9K 615.1K +438% $0
D 2025-01-14 2025-01-10 SLS Stergiou Angelos M. Pres, CEO, Dir A - Grant $0.00 +385.8K 385.8K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-01-10 A A 243,900 $0.00 859,032 D — — (F2) The Reporting Person received an award of 243,900 restricted stock units on January 10, 2025, which shall vest in full on December 1, 2025, provided that the Reporting Person remains in service with the Issuer through each such vesting date.
2 Common Common Stock 2025-01-10 A A 257,000 $0.00 615,132 D — — (F1) The Reporting Person received an award of 257,000 restricted stock units on January 10, 2025, which shall vest as follows: (i) 25% on December 1, 2025 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date.
3 Derivative Stock Option (Right to Buy) 2025-01-10 A A 385,750 $0.00 385,750 D $0.95 · — to 2035-01-10 385,750 Common Stock (F3) One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 10, 2025 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.